Hosted on MSN1h
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...
Who's afraid of the EU-Mercosur Agreement?
Vilified by some, defended by others and misunderstood by many, the “Mercosur Agreement” is a passionate subject these days ...
stockhead12h
Rare opportunities – ASX health stocks tackling unmet medical needs
Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.
PipelineReview.com12h
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
PALO ALTO, CA, USA I February 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...
The Scottish Farmer12h
Veterinary generics face rising costs and regulatory hurdles
Despite their market presence, generic veterinary medicine producers face increasing regulatory and financial pressures. While EU regulations have ‘improved harmonisation’ in the sector, they have ...
EMA creates advice portal for some high-risk medical devices
The European Medicines Agency said the portal will enable consultations with medical device expert panels that can promote faster access to new technologies.